Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 6
Submit an article Journal homepage
604
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective

Ellen K. RitchieDepartment of Hematology/Oncology, Weill Cornell Medical College of Cornell University, New York, NY, USA; Correspondence[email protected]
View further author information
,
Dominick Latremouille-ViauAnalysis Group, Inc, Montreal, Canada; View further author information
,
Annie GuerinAnalysis Group, Inc, Montreal, Canada; View further author information
,
Irina PivnevaAnalysis Group, Inc, Montreal, Canada; View further author information
,
Karen HabuckyNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
,
Briana NdifeNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
,
George J. JosephNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA; View further author information
&
Ehab L. AtallahMedical College of Wisconsin, Milwaukee, WI, USAView further author information
 show all
Pages 1476-1484 | Received 14 Aug 2018, Accepted 13 Oct 2018, Published online: 22 Jan 2019

References

  • Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973–1998). Cancer. 2003;97:2229–2235.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 4. 2018—January 24, 2018. [Internet]; [cited 2018 May 1]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, Version 1.2016 [Internet]; [cited 2018 May 1]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/cml.pdf
  • Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
  • Rea D, Rousselot P, Guilhot F, et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood. 2012;120:916.
  • Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–854.
  • Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–1531.
  • U.S. Food and Drug Administration. TASIGNA® (nilotinib) Medication Guide [Internet]; 2017 [cited 2018 Jan 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf
  • Baccarani M, Deininger MW, Rosti G, et al. European leukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
  • Saussele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
  • Zhen C, Wang YL. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. J Mol Diagn. 2013;15:556–564.
  • Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.
  • Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.
  • Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. Jco. 2014;32:415–423.
  • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.
  • Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res. 2012;36:689–693.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.